Despite available treatments, many patients with acute myeloid leukaemia, or AML, are in need of additional therapeutic options. Thankfully, there hundreds of clinical trials for new interventions that could rectify this, but which options can we start to consider, for which patients and when? To answer our questions on this topic, we’ve invited the expertise of Dr Navel Daver, Associate Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas.

References:

• Swords, et al. Blood. 2018;131(13):1415-1424
• Stahl, et al. Curr Oncol Rep. 2019;21(4):37
• Yee at al. Blood (2014) 124 (21): 116.
• Montesinos et al. Future Oncol. 2020 May;16(13):807-815.
• Ades, et al. ASCO 2020. Abstract 7506
• DeAngelo, et al. Blood (2017) 130 (Supplement 1): 894.
• Ravandi, et al. Lancet Haematol. 2019 Sep; 6(9): e480-e488
• Hofmann, et al. J Clin Med. 2019 Feb; 8(2): 200.

This series is supported by educational grants from Servier Pharmaceuticals LLC and Takeda, who have had no influence on the content or choice of faculty